David Tsai is co-head of Pillsbury’s Taiwan practice and also resident in the San Francisco office.  David focuses his practice on intellectual property, patent, trade secret, trademark, copyright, complex breach of contract, and product defect litigation in courts and international arbitration tribunals.

David represents world-class corporations innovating biotechnology, pharmaceuticals, medical devices, software (internet and mobile apps), and hardware (semiconductors, set-top boxes, smartphones, solar wafers and light-emitting diodes/LED/OLED).  In addition to litigation, his experience includes preparing and prosecuting U.S. electrical engineering patent applications, drafting patentability, freedom-to-operate and non-infringement opinions, as well as inter partes review (IPR) petitions.  He represents his clients in patent negotiations, licensing and overall intellectual property strategy. David has been quoted in various business and technology publications including The New York Times and has written and lectured internationally on Hatch-Waxman/Abbreviated New Drug Application (ANDA) litigation, standard essential patents, FRAND/RAND royalties, internet software applications, and U.S. patent law. He serves as one of the 18 Lawyer Representatives to the U.S. District Court, Northern District of California.